Hemoglobinopathies  >>  Zolinza (vorinostat)  >>  Phase 2
Welcome,         Profile    Billing    Logout  

1 Trials

Remove FilterRemove Filter

Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Zolinza (vorinostat) / Merck (MSD)
NCT01000155: Efficacy of Vorinostat to Induce Fetal Hemoglobin in Sickle Cell Disease

Terminated
2
5
US
vorinostat, SAHA
Dana-Farber Cancer Institute, Brigham and Women's Hospital, Boston Children's Hospital, Merck Sharp & Dohme LLC
Sickle Cell Disease, Sickle Cell Anemia
10/14
10/14

Download Options